MOTS-c Human Studies: What Has Actually Been Tested in People?

MOTS-c is marketed online as a mitochondrial peptide that fights aging, sharpens metabolism, melts fat, and mimics the benefits of exercise in a syringe. Almost none of that marketing distinguishes between two very different bodies of research: studies that measure the MOTS-c a person's own mitochondria already make, and studies that actually give people a synthetic version of the peptide. That distinction is not a technicality. It is close to the entire story.

In its 2026 review of MOTS-c-related substances for the pharmacy-compounding bulk drug substances list, FDA staff searched the published literature and reported that they did not identify clinical studies in which a MOTS-c-related substance had actually been administered to human participants. The full analysis is in the FDA briefing document for MOTS-c-related bulk drug substances. That is a striking gap for a peptide with hundreds of published papers behind it, and understanding why the gap exists means separating the research into the categories that follow: naturally occurring MOTS-c, exercise-induced changes in the body's own peptide, cell and animal experiments, and the small, very recent handful of studies that have actually injected something into a person.

The key point: most of the human evidence behind MOTS-c is observational, meaning it measures the peptide the body already produces and asks whether its level correlates with age, fitness, or disease. Only two things resembling an actual human administration trial exist. One tested a chemically modified analog, not MOTS-c itself, and found a mixed result. The other, a placebo-controlled trial of the real peptide, only opened for enrollment in 2026 and has no results yet. Online claims that MOTS-c "has been tested in humans and is safe" almost always rest on the first category, the analog, or on no clinical data at all.

How Much Direct Human MOTS-c Research Actually Exists?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was first described in 2015 by a research team led by Changhan Lee, in a paper reporting that a 16-amino-acid peptide encoded within mitochondrial DNA regulates insulin sensitivity and metabolic homeostasis in cells and mice. Review the original MOTS-c discovery paper. In the decade since, MOTS-c has generated a large and genuinely interesting research literature, but that literature is heavily weighted toward three things: laboratory experiments in cells, treatment experiments in mice and rats, and observational studies that measure naturally occurring MOTS-c in human blood or muscle. Studies that inject a synthetic MOTS-c product into a person and then measure what happens are a much smaller, much newer category, and telling these apart is the single most useful thing a reader can do before believing a MOTS-c claim.

Studies Measuring Naturally Occurring MOTS-c

The largest share of human MOTS-c research does not administer anything. It draws blood or muscle tissue and measures the peptide a person's mitochondria are already producing, then looks for a correlation with age, body composition, or disease.

Aging: A 2020 study measured plasma and skeletal-muscle MOTS-c in healthy men grouped by age: young (18 to 30), middle-aged (45 to 55), and older (70 to 81). Circulating MOTS-c was 11 percent lower in the middle-aged group and 21 percent lower in the older group compared with young men, yet skeletal-muscle MOTS-c expression was roughly 1.5-fold higher in both older groups than in the young group. In the older men, higher muscle MOTS-c was associated with better muscle quality (a higher maximal leg-press load relative to thigh size). Review the MOTS-c aging and skeletal muscle study. That is a genuinely useful, well-controlled human finding, and it is also a two-directional one: blood levels go down with age while muscle levels go up, which is a considerably more complicated story than the "MOTS-c declines with age" framing used in most marketing.

Diabetes and obesity: Multiple independent groups have reported that circulating MOTS-c tends to run lower in people with poorly controlled type 2 diabetes and in obese children. Review the MOTS-c and diabetes biomarker study and a pediatric-obesity MOTS-c study reporting significantly lower serum MOTS-c in obese boys, with no significant difference in obese girls. A 2024 meta-analysis pooling 602 participants across six case-control studies and one cross-sectional study found that circulating MOTS-c was significantly lower in people with type 2 diabetes overall, while its relationship to obesity specifically was less consistent, sometimes trending higher rather than lower. Review the MOTS-c metabolic-disease meta-analysis. A separate small study found that plasma MOTS-c correlated with insulin-sensitivity measures in lean adults but not in obese adults, suggesting the relationship itself changes once metabolic disease is present. Review the MOTS-c and insulin sensitivity in lean versus obese adults study.

Other conditions: Lower circulating MOTS-c has also been reported in people with chronic kidney disease, coronary endothelial dysfunction, chronic obstructive pulmonary disease, and obstructive sleep apnea. Each of these is a real, published association. None of them tested whether giving a person MOTS-c would improve kidney function, blood-vessel health, lung function, or sleep apnea. An association observed in blood is a hypothesis about MOTS-c's role in disease, not a demonstration that adding more of it would help.

Research Showing Exercise Changes MOTS-c Levels

MOTS-c is frequently called an "exercise mimetic," a label that comes from a real and interesting body of research, but one that is more mixed than most marketing acknowledges.

The most cited human exercise study had healthy young men cycle to the point of fatigue on a stationary bike, then measured MOTS-c in muscle and blood before, during, and after exercise, plus after a four-hour rest. Muscle MOTS-c rose nearly 12-fold after exercise and remained partially elevated four hours later, while plasma MOTS-c rose by roughly 50 percent before returning to baseline. This research came out of the same laboratory that first identified MOTS-c and separately showed that injected MOTS-c improved treadmill running capacity in young, middle-aged, and old mice, with old mice roughly doubling their running time. Review the exercise-induced MOTS-c and mouse physical-performance study.

A separate, independently conducted randomized study reached a more modest conclusion. Thirty healthy adults were randomized to a single session of endurance cycling, resistance exercise, or no exercise, with muscle biopsies and blood draws before and after. Circulating levels of a related mitochondrial peptide, humanin, rose significantly after endurance exercise but not resistance exercise, while MOTS-c itself only showed a nonsignificant trend toward increasing, and plasma MOTS-c levels were not correlated with participants' fitness, leg strength, or VO2 max. Review the randomized acute-exercise MOTS-c study. A third line of research complicates the picture further: professional endurance athletes have been found to have lower resting serum MOTS-c than untested controls, and a study correlating serum MOTS-c with physical tests found it tracked with jump power and leg-muscle mass rather than with aerobic capacity. Review the MOTS-c levels in professional athletes study and the MOTS-c and muscle-strength correlation study.

Put together, these studies do not agree on a single, simple rule. A specific, fatiguing single-session protocol produced a dramatic increase in one lab; a different single-session protocol in an independent randomized trial produced only a nonsignificant trend; and habitually training as a professional endurance athlete was associated with lower resting levels, not higher ones. "Exercise raises MOTS-c" is a real research question, not a settled fact, and none of these studies gave anyone an injection of the peptide itself. They describe how a person's own mitochondria respond to physical stress, which is a different question from whether injecting MOTS-c reproduces any part of that response.

Cell and Animal Experiments

The specific, mechanistic claims attached to MOTS-c, that it activates AMPK, increases insulin sensitivity, protects bone, or extends lifespan, trace almost entirely to experiments in cultured cells and rodents, not to people.

• The founding experiments: The original 2015 paper that identified MOTS-c used human cell lines (HEK293 and HeLa cells) to characterize the peptide's molecular mechanism, then treated mice with MOTS-c and reported that it prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity.
• Physical performance and aging: Elderly mice (23.5 months old) treated with MOTS-c three times weekly showed a trend toward increased lifespan, a 6.4 percent increase in median lifespan and a 7 percent increase in maximum lifespan compared with untreated mice, alongside improved treadmill running capacity.
• Bone: In ovariectomized mice, a model of menopause-related bone loss, MOTS-c injections reduced bone loss by suppressing bone-resorbing cell formation. Review the MOTS-c and ovariectomy-induced bone loss study.
• Autoimmune and infectious disease: MOTS-c reduced pancreatic inflammation and delayed diabetes onset in NOD mice, a model of type 1 diabetes, and pretreatment improved survival in mice given a lethal MRSA infection or endotoxin-induced sepsis.
• Pain: In a standard rodent inflammatory-pain model, MOTS-c injections reduced pain behavior and inflammatory cytokines through the same AMPK pathway implicated in its metabolic effects.

Each of these findings is a legitimate, published result, and each one used doses given by intraperitoneal injection in rodents (commonly in the range of 0.5 to 50 milligrams per kilogram of body weight, depending on the model), doses that cannot be converted directly into a human milligram amount without the pharmacokinetic, toxicology, and clinical studies that have not yet been done. A mouse that runs twice as long on a treadmill after an injection is a genuinely promising signal for future research. It is not evidence about what the same molecule would do in a person.

Studies Administering Synthetic MOTS-c to Humans

This is the category the FDA's reviewers searched for and largely could not find, and it is worth being precise about what does and does not exist here, because two different things get described online as "MOTS-c human trials."

CB4211, a modified analog, not MOTS-c itself: A biotechnology company called CohBar developed CB4211, a chemically modified analog of MOTS-c, and tested it in a Phase 1a/1b trial (NCT03998514) that ultimately enrolled 88 participants. The trial gave single and multiple ascending subcutaneous doses to healthy non-obese volunteers, then tested a 28-day daily dosing regimen in people with nonalcoholic fatty liver disease. The primary outcomes were safety, tolerability, and pharmacokinetics, not a treatment benefit. According to the sponsor's topline results, CB4211 met its primary safety endpoint with no serious adverse events, but the study had to be paused in 2018 to amend its protocol after persistent, painless injection-site bumps turned out to be common. In the liver-disease portion, CB4211 reduced liver enzymes (ALT and AST) more than placebo, but the more direct measure of disease, liver fat measured by MRI, improved by a similar amount in both the drug and placebo groups. CohBar was later dissolved, and clinical development of CB4211 was discontinued. Whatever this trial shows, it is evidence about a modified analog molecule, not about MOTS-c's own amino-acid sequence, in the same way that research on Epithalamin does not automatically apply to Epitalon.

The first trial of native MOTS-c itself: As of this writing, one registered trial tests the unmodified MOTS-c peptide directly in people: NCT07505745 (MOTS-MET), a Phase 2a, randomized, double-blind, placebo-controlled study of once-daily subcutaneous MOTS-c for 12 weeks in adults with prediabetes and overweight or obesity. The trial began enrolling in February 2026, is currently recruiting at a single site, and its primary completion is not expected until February 2027. It has produced no results yet. This single fact accounts for most of the gap the FDA identified: the only placebo-controlled human trial of actual MOTS-c had barely opened for enrollment by the time regulators reviewed the literature, and the completed human trial that did exist tested a different, modified molecule.

Clinical Outcomes Versus Metabolic Biomarkers

A clinical outcome is something that changes a person's actual health or function: less diabetes, fewer fractures, measurably reduced liver disease. A metabolic biomarker is a laboratory value that may or may not track with any of those outcomes. Keeping this distinction in view is the fastest way to evaluate a MOTS-c claim.

In the completed CB4211 analog trial, the biomarkers moved (liver enzymes improved relative to placebo) while the more clinically meaningful measure, imaged liver fat, did not differ from placebo. That is close to the opposite of what a marketing claim needs: a biomarker changed without the underlying disease measure moving. In the observational literature on naturally occurring MOTS-c, the "outcomes" are correlations, lower blood MOTS-c alongside worse HbA1c, lower MOTS-c alongside more advanced kidney disease, which describe an association discovered in a snapshot of blood, not a benefit demonstrated by giving anyone a treatment. Even the ongoing MOTS-MET trial, the most rigorous human study of MOTS-c to date, has chosen a biomarker (the Matsuda Index, a laboratory-derived measure of insulin sensitivity from an oral glucose tolerance test) as its primary outcome rather than a harder endpoint like a diabetes diagnosis prevented, which is a reasonable choice for an early-phase trial but still not the same thing as a proven clinical benefit.

No study identified anywhere in this article has measured a hard clinical outcome, weight lost and kept off, diabetes prevented, a fracture avoided, in a person who received synthetic MOTS-c. That gap is the honest current state of the evidence, not a detail marketing has simply forgotten to mention.

Online Claims That Blur These Categories Together

Peptide marketing routinely collapses the four categories above into a single, confident-sounding claim. A few of the most common examples:

• Dosing protocols with no human source: Product pages often specify daily microgram doses for weight loss or performance. None of that comes from human pharmacokinetic data, because none has been published; it is extrapolated from rodent milligram-per-kilogram dosing or simply copied between websites.
• "Declines with age, so more is better": The aging studies above show that circulating MOTS-c drops with age while muscle MOTS-c rises, a pattern that does not map cleanly onto "add more of it back." An association observed across age groups is not evidence about what happens if that specific level is artificially restored with an injection.
• "Exercise mimetic" stretched into "exercise replacement": The genuine, if mixed, exercise research above measured the body's own MOTS-c response to physical activity. It says nothing about whether an injection reproduces the cardiovascular, muscular, and metabolic benefits that come from actually exercising.
• CB4211's safety data presented as MOTS-c's safety data: Because CB4211 is the only completed human dosing trial in this space, its topline safety results are sometimes cited generically as proof that "MOTS-c has been tested in humans and is safe," without clarifying that the tested molecule was a modified analog, that persistent injection-site reactions were common enough to pause the trial, and that its one imaged efficacy measure did not beat placebo.

Outside of registered trials, the U.S. Anti-Doping Agency has noted that people who report buying MOTS-c online for "research purposes only" have described side effects including increased heart rate or palpitations, injection-site irritation, insomnia, and fever, with no data on what happens with long-term use. Review USADA's overview of MOTS-c risks. Self-reports like these cannot establish how common a side effect is or what caused it, but they are a reminder that "no completed human safety trial of MOTS-c itself exists" is not the same as "no one has experienced anything."

The Bottom Line

MOTS-c is a real, naturally occurring mitochondrial peptide with a substantial and still-growing research base, most of which measures the body's own peptide or tests it in cells and rodents. Human observational studies consistently link lower circulating MOTS-c to aging and metabolic disease, and a modified analog has completed Phase 1 human safety testing with a mixed result. What has not yet happened, as the FDA's own 2026 review found, is a completed clinical trial giving people synthetic MOTS-c itself and measuring whether it produces a genuine clinical benefit. That trial exists now, opened for enrollment in 2026, and has no results. Until it, or a study like it, reports data, claims that MOTS-c injections reverse aging, replace exercise, or treat obesity in people rest on research that was never designed to test those specific questions.

For a broader look at MOTS-c's proposed benefits, documented risks, and the FDA's full 2026 review, see AlphaMD's MOTS-c benefits, risks, and side effects overview, and for the regulatory context behind the 503A Bulks List vote, see AlphaMD's report on the FDA advisory vote involving BPC-157, TB-500, KPV, and MOTS-c.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. MOTS-c is not currently an FDA-approved drug. Speak with a licensed medical provider before using any medication, peptide, supplement, or injectable product.